ICON PLC Aktie

 

Citi swept through its life science tools and diagnostics coverage on Wednesday, opening a 90-day upside catalyst watch on Agilent Technologies (NYSE:A) while trimming its price target on Icon PLC (NASDAQ:ICLR) following a turbulent earnings season for the sector. Alongside those moves, the firm named Agilent its top tools pick, Natera (NASDAQ:NTRA) its top diagnostics ... Citi Flags Agilent Technologies, Cuts Icon PLC Target, and More The post Citi Flags Agilent Technologies, Cuts Icon PLC Target, and More appeared first on 24/7 Wall St.....

NEW YORK, March 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ICON plc ("ICON" or the "Company") (NASDAQ: ICLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns......

NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ICON plc ("ICON" or the "Company") (NASDAQ: ICLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns......

(NASDAQ: ICLR) NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating ICON plc (NASDAQ: ICLR) following the company's disclosure on February 12, 2026, that an internal accounting investigation uncovered preliminary evidence that revenue for fiscal years 2023 and......

ICLR Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- Investors in ICON plc (NASDAQ: ICLR) saw the price of their shares drop about 49% during trading on February 12, 2026, after the company disclosed its investigation into the......

MILWAUKEE, Feb. 12, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against ICON (NASDAQ: ICLR). The investigation results from inaccurate statements ICON may have made regarding its financial statements, business operations and prospects. Click here to......

ICON Plc shares plunged in premarket trading after the health care services contractor said it may have overstated some of its past revenue and pulled its guidance for the year....

Investigation's preliminary indications are that 2023 and 2024 revenue may have been overstated by less than 2% for each fiscal yearDUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) today announced that it intends to release its fourth quarter and full year 2025 earnings results on or prior to April 30, 2026. The Company also announced an ongoing internal investigation initiated by the Audit Committee of the Board of Directors in late October 2025 into certain of the Company's accounting practices and controls, following concerns reported to the Audit Committee through Company management. Outside legal counsel is conducting the investigation with the support of forensic and technical accounting firms. The investigation primarily focuses on revenue recognition in fiscal years 2023 through 2025. The Company is in the process of evaluating the design and operation of certain internal controls over financial reporting and expects to report one or more material weaknesses as a result. While the investigation...

Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Icon PLC (ICLR) delivered earnings and revenue surprises of +0.91% and +3.03%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?...

Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced that Dr. Steve Cutler has informed the Board of his decision to retire as Chief Executive Officer and the Board has appointed Mr. Barry Balfe, ICON's Chief Operating Officer, to succeed Dr. Cutler as Chief Executive Officer effective 1 October 2025. Mr. Balfe has also been appointed to the Board. Dr. Cutler will continue to serve on the Board as a non-executive director to facilitate a smooth transition. Mr. Balfe has deep knowledge of the CRO industry and has served as ICON's Chief Operating Officer since January 2025. Prior to his appointment as Chief Operating Officer, Mr. Balfe was appointed to the ICON executive leadership team in 2019 and served as President of Functional Services and then as President of Pharma Solutions. ICON's Chair, Mr. Ciaran Murray said, “Barry has an outstanding record of success in leadership positions in ICON, most recently in his role as Chief Operating Of...

DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation powered by healthcare intelligence, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 22, 2025 were duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 11, 2025 and are available on the ICON plc website. Forms of Proxy were received by ICON plc before the meeting, appointing proxies and giving them the following voting instructions: RESOLUTION NUMBER RESOLUTION    TOTAL NUMBER OF VOTES    VOTE FOR    VOTE AGAINST    VOTE WITHHELD                   1.1   To re-elect Mr. Ciaran Murray    59,889,939    58,573,183    1,307,430    9,326 1.2   To re-elect Dr. Steve Cutler    59,889,939    59,259,952    619,506    10,481 1.3   To re-elect Mr. Rónán Murphy    59,889,939    58,434,915    1,444,942    10,082 1.4   To re-elect Dr. John Climax    59,889,939  ...

Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that it will release its financial results for the second quarter 2025 after the market closes on Wednesday, July 23, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, July 24, 2025 at 8:00am ET. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under “Events”. A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward an...

Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

LOS ANGELES, April 10, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against ICON plc ("ICON" or the "Company") (NASDAQ: ICLR). IF YOU SUFFERED A LOSS ON YOUR ICON INVESTMENTS, CLICK......

SAN DIEGO, April 9, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of ICON PLC (NASDAQ: ICLR) ordinary shares between July 27, 2023 and January 13, 2025, all dates inclusive (the "Class Period"), have until this upcoming Friday, April 11, 2025 to seek......

NEW YORK, April 8, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period"), of the important April 11, 2025 lead plaintiff......